Anti-Human CD20 Reference Antibody (NAV006, RUO) (HY257386)

Name: Anti-Human CD20 Reference Antibody (NAV006, RUO)
Brand: abinScience
SKU: HY257386
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY257386
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	NAV006
Biological activity	NAV006 (0.78-100 nM) specifically binds to CD20-positive Ramos cells in a dose-dependent manner (K d =30.5 nM) [1]. NAV006 is able to mediate a\r\nmore robust Fc receptor‑dependent cytotoxic activity (ADCC)\r\nagainst Daudi target cells in the presence of the immunosuppressive\r\nCA125 compared with parent Rituximab () [1]. NAV006 (1 mg/kg; i.p.) mediates antitumor activity in NCG mice with human lymphoma Raji cells (with a tumor growth inhibition of 95%) [2].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P11836
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	NAV006
Background	B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). 1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111 2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015 3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739 4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
References	1. Grasso L, et al. Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression. Oncol Lett. 2022;23(1):2. [HY257386] 2. Grasso L, et al. Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo. Antib Ther. 2025;8(3):171-176. Published 2025 Apr 24. [HY257386]
Note	For research use only. Not suitable for clinical or therapeutic use.